During the past decade, Intermed Groupe Santé conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Intermed Groupe Santé" are "Atopic Dermatitis" (1 trials), "COVID-19" (1 trials), "Clostridium Difficile Infection" (1 trials), "Clostridium Difficile Infection Recurrence" (1 trials) and "Dermatitis, Atopic" (1 trials). Many other conditions were trialed in "Intermed Groupe Santé" in a lesser frequency.

Most popular intervention types in "Intermed Groupe Santé" are "Drug" (4 trials), "Biological" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Abrocitinib 200 mg" (2 trials), "ART24" (1 trials), "Abrocitinib 100 mg" (1 trials) and "Clostridium difficile vaccine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Intermed Groupe Santé" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Intermed Groupe Santé". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Intermed Groupe Santé, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Intermed Groupe Santé, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".